Inactivated Mouse Urokinase

$495$895

Clear
SKU: MUPA-IN Categories: ,

Product Description

Inactivated Mouse Urokinase

Inactivated two-chain HMW mouse urokinase, recombinantly produced in insect cells. Prepared from active mouse uPA by active site-specific inactivation with Phe-Pro-Arg chloromethyl ketone followed by removal of excess inhibitor by extensive dialysis.

Gene ID: 18792
Swiss-Prot/UniProt ID: P06869

View sample datasheet
View sample certificate of analysis
View material safety data sheet
Ask a question about this product

Additional Information

Purity

Source

Molecular Weight

Extinction Coefficient

Species

Storage

Shipping Conditions

Expiration

Form

Buffer

Sample Size

Sample Concentration

Sample Volume

Gene Name

Gene ID

UniProt ID

1. Merchan JR, Tang J, Hu G et-al. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. J. Natl. Cancer Inst. 2006;98 (11): 756-64. doi:10.1093/jnci/djj208Pubmed citation

2. Suelves M, Vidal B, Serrano AL et-al. uPA deficiency exacerbates muscular dystrophy in MDX mice. J. Cell Biol. 2007;178 (6): 1039-51. doi:10.1083/jcb.200705127Free text at pubmedPubmed citation

3. Bryer SC, Fantuzzi G, Van rooijen N et-al. Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration. J. Immunol. 2008;180 (2): 1179-88. J. Immunol. (link)Pubmed citation

4. Ilkovitch D, Handel-fernandez ME, Herbert LM et-al. Antitumor effects of Mucin 1/sec involves the modulation of urokinase-type plasminogen activator and signal transducer and activator of transcription 1 expression in tumor cells. Cancer Res. 2008;68 (7): 2427-35. doi:10.1158/0008-5472.CAN-07-5651Pubmed citation

5. Van den broeck T, Stevenaert F, Taveirne S et-al. Ly49E-dependent inhibition of natural killer cells by urokinase plasminogen activator. Blood. 2008;112 (13): 5046-51. doi:10.1182/blood-2008-06-164350Pubmed citation

6. Jo M, Takimoto S, Montel V et-al. The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice. Am. J. Pathol. 2009;175 (1): 190-200. doi:10.2353/ajpath.2009.081053Free text at pubmedPubmed citation

8. Sisson TH, Nguyen MH, Yu B et-al. Urokinase-type plasminogen activator increases hepatocyte growth factor activity required for skeletal muscle regeneration. Blood. 2009;114 (24): 5052-61. doi:10.1182/blood-2008-12-196212Free text at pubmedPubmed citation

9. Botkjaer KA, Deryugina EI, Dupont DM et-al. Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism. Mol. Cancer Res. 2012;10 (12): 1532-43. doi:10.1158/1541-7786.MCR-12-0349Free text at pubmedPubmed citation

10. Ilkovitch D, Carrio R, Lopez DM. uPA and uPA-receptor are involved in cancer-associated myeloid-derived suppressor cell accumulation. Anticancer Res. 2012;32 (10): 4263-70. Anticancer Res. (link)Pubmed citation

11. Sanderson-smith ML, Zhang Y, Ly D et-al. A key role for the urokinase plasminogen activator (uPA) in invasive Group A streptococcal infection. PLoS Pathog. 2013;9 (7): e1003469. doi:10.1371/journal.ppat.1003469Free text at pubmedPubmed citation

12. Wu F, Catano M, Echeverry R, et al. Urokinase-type plasminogen activator promotes dendritic spine recovery and improves neurological outcome following ischemic stroke. J Neurosci. 2014;34(43):14219-32. Link to article

13. Endo-munoz L, Cai N, Cumming A, et al. Progression of Osteosarcoma from a Non-Metastatic to a Metastatic Phenotype Is Causally Associated with Activation of an Autocrine and Paracrine uPA Axis. PLoS ONE. 2015;10(8):e0133592. Link to article.